These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 28299514)

  • 1. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
    Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
    Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
    Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
    Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of circulating tumor cells in patients with small-cell lung cancer.
    Wang YL; Liu CH; Li J; Ma XP; Gong P
    Tumori; 2017 May; 103(3):242-248. PubMed ID: 28218384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Aggarwal C; Wang X; Ranganathan A; Torigian D; Troxel A; Evans T; Cohen RB; Vaidya B; Rao C; Connelly M; Vachani A; Langer C; Albelda S
    Lung Cancer; 2017 Oct; 112():118-125. PubMed ID: 29191584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
    Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
    Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
    Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
    Smit EF; Socinski MA; Mullaney BP; Myrand SP; Scagliotti GV; Lorigan P; Reck M; Ciuleanu T; von Pawel J; Karaseva NA; Szczesna A; Ohannesian D; Powell E; Hozak RR; Hong S; Guba SC; Thatcher N
    Ann Oncol; 2012 Jul; 23(7):1723-9. PubMed ID: 22186609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
    Imai H; Mori K; Watase N; Fujimoto S; Kaira K; Yamada M; Minato K
    Can Respir J; 2016; 2016():5405810. PubMed ID: 27445549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study.
    Zhu C; Huang J; Jin X; Zhang C; Zhu C; Lv M; Chen S; Du X; Feng G
    Medicine (Baltimore); 2024 Jun; 103(23):e38487. PubMed ID: 38847733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
    Belani CP; Dahlberg SE; Rudin CM; Fleisher M; Chen HX; Takebe N; Velasco MR; Tester WJ; Sturtz K; Hann CL; Shanks JC; Monga M; Ramalingam SS; Schiller JH
    Cancer; 2016 Aug; 122(15):2371-8. PubMed ID: 27163943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.
    Abdel-Rahman O
    Clin Respir J; 2018 Oct; 12(10):2519-2524. PubMed ID: 30073795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.
    Normanno N; Rossi A; Morabito A; Signoriello S; Bevilacqua S; Di Maio M; Costanzo R; De Luca A; Montanino A; Gridelli C; Rocco G; Perrone F; Gallo C
    Lung Cancer; 2014 Aug; 85(2):314-9. PubMed ID: 24882383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
    Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Sato I; Tani N; Ogura Y; Hirose K; Takeda T
    Thorac Cancer; 2020 Sep; 11(9):2740-2742. PubMed ID: 32706170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients.
    Shi WL; Li J; Du YJ; Zhu WF; Wu Y; Hu YM; Chen YC
    Med Oncol; 2013 Dec; 30(4):755. PubMed ID: 24178178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.